Key result
Transcriptional alterations were highly specific to individual genetic causes of cardiac hypertrophy in four transgenic mouse models, with no single gene consistently upregulated across all models.
Why the study?
Do different genetic causes of cardiac hypertrophy elicit divergent transcriptional responses in transgenic mouse models?
Do different genetic causes of cardiac hypertrophy elicit divergent transcriptional responses in transgenic mouse models?
Different genetic causes of cardiac hypertrophy produce distinct transcriptional profiles rather than a single common gene program, suggesting the potential for condition-specific therapeutic approaches.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for etiology-specific therapies in genetic hypertrophy; requires human validation before any clinical consideration.
To define molecular mechanisms of cardiac hypertrophy, genes whose expression was perturbed by any of four different transgenic mouse hypertrophy models [protein kinase C-epsilon activation peptide (PsiepsilonRACK), calsequestrin (CSQ), calcineurin (CN), and Galpha(q)] were compared by DNA microarray analyses using the approximately 8,800 genes present on the Incyte mouse GEM1. The total numbers of regulated genes (tens to hundreds) correlated with phenotypic severity of the model (Galpha(q) > CN > CSQ > PsiepsilonRACK), but demonstrated that no single gene was consistently upregulated. Of the three models exhibiting pathological hypertrophy, only atrial natriuretic peptide was consistently upregulated, suggesting that transcriptional alterations are highly specific to individual genetic causes of hypertrophy. However, hierarchical-tree and K-means clustering analyses revealed that subsets of the upregulated genes did exhibit coordinate regulatory patterns that were unique or overlapping across the different hypertrophy models. One striking set consisted of apoptotic genes uniquely regulated in the apoptosis-prone Galpha(q) model. Thus, rather than identifying a single common hypertrophic cardiomyopathy gene program, these data suggest that extensive groups of genes may be useful for the prediction of specific underlying genetic determinants and condition-specific therapeutic approaches.
No takes yet. Share an insight, caveat, or question.
Aronow et al. (2001) studied Cardiac hypertrophy. Transgenic mouse hypertrophy models was evaluated on Gene expression profiles. Transcriptional alterations were highly specific to individual genetic causes of cardiac hypertrophy in four transgenic mouse models, with no single gene consistently upregulated across all models.
Synapse has enriched 10 related papers. Consider them for comparative context: